FDA Approves First Oral Treatment for Common Blood Cancer
Patients with chronic lymphocytic leukemia now have a new treatment option that doesn't require chemotherapy and allows time off from treatment. The FDA approved the first all-oral, fixed-duration therapy for this common adult leukemia.
Thousands of adults diagnosed with chronic lymphocytic leukemia each year just got a game-changing new treatment option.
The FDA approved a groundbreaking combination therapy from AbbVie and AstraZeneca on Friday. This marks the first time patients with previously untreated CLL can take an all-oral medication that doesn't require continuous use.
CLL is one of the most common forms of leukemia in adults. The disease causes bone marrow to produce too many dysfunctional white blood cells, weakening the immune system over time.
The new treatment combines two drugs called Venclexta and Calquence. Patients take both medications for a fixed period, then get a break from treatment instead of staying on medication indefinitely.
The approval came after strong results from a major clinical trial. Researchers found that 77% of patients using the combination therapy were progression-free at three years, compared to 67% receiving standard chemotherapy.
Even more promising, the new treatment reduced the risk of disease progression or death by 35% compared to traditional chemoimmunotherapy. The median time before the disease worsened couldn't even be calculated yet for patients on the new treatment, while chemotherapy patients saw progression at 47.6 months.
Why This Inspires
This approval represents a fundamental shift in how doctors can treat CLL. Patients no longer have to choose between chemotherapy side effects or staying on medication forever.
The fixed-duration approach means people can finish treatment and return to normal life without daily pills. That freedom matters deeply to patients managing chronic conditions while trying to live fully.
The targeted therapy approach also means fewer side effects than traditional chemotherapy. Patients report better quality of life during treatment, making it easier to work, spend time with family, and maintain their routines.
For the thousands diagnosed with CLL each year, this approval offers genuine hope for better outcomes and more time feeling well.
Based on reporting by Google: new treatment approved
This story was written by BrightWire based on verified news reports.
Spread the positivity!
Share this good news with someone who needs it
